Table 1.
Characteristics of Patients with JMTV Infections in Northeastern China, 2010 through 2018.
| Characteristics | Patients |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
| Diagnosis method | ||||||||||||
| RNA-seq of skin biopsies (RPM) | 2334 | 287 | 105 | 105 | NA | NA | NA | NA | NA | NA | NA | NA |
| qRT-PCR of blood or serum RNA | + | + | + | + | + | − | − | − | − | − | − | − |
| IgG antibodiesa | ||||||||||||
| Acute phase (days of sample collectionb) | <20 (5) | NA | <20 (2) | NA | <20 (3) | <20 (1) | <20 (1) | <20 (4) | <20 (4) | <20 (4) | <20 (4) | <20 (3) |
| Convalescent phase (days of sample collection) | NA | NA | NA | NA | 80 (41) | 80 (15) | 160 (7) | 160 (14) | 160 (17) | 80 (57) | 80 (28) | 160 (11) |
| Epidemiological feature | ||||||||||||
| Sex | F | F | F | F | M | F | F | M | M | F | F | F |
| Age-yr | 53 | 33 | 69 | 43 | 28 | 61 | 2 | 46 | 25 | 46 | 62 | 41 |
| Tick-bite location | Ear | Scalp | Back/Arm | Back | Abdomen/Back/Axilla | Back | Scalp | Check | Axilla | Scalp | Scalp | Back/Neck |
| Sample collection-yr | 2016 | 2016 | 2016 | 2016 | 2010 | 2012 | 2012 | 2012 | 2012 | 2013 | 2014 | 2018 |
| Clinical manifestation | ||||||||||||
| Elevated temperature (°C) | − | − | − | − | 39 | − | 39 | 39 | 38·5 | − | − | 37·5 |
| Asthenia | − | − | + | − | + | − | − | − | − | + | − | + |
| Headache | − | − | + | − | + | + | − | + | + | + | + | + |
| Anorexia | − | − | − | − | + | − | − | − | − | + | − | − |
| Myalgia | − | − | − | − | + | − | − | − | + | − | − | + |
| Arthralgia | − | − | − | − | − | − | − | − | − | − | − | − |
| Nausea/Vomiting | − | − | − | − | + | + | − | − | − | + | − | − |
| Lymphadenopathy | + | + | − | − | − | − | − | − | − | − | − | − |
| Seizure | − | − | − | − | + | − | − | − | − | − | − | − |
| Skin lesions | ||||||||||||
| Eschar | + | + | + | − | − | − | − | − | + | − | − | − |
| Rash | − | − | − | − | − | − | − | − | − | − | − | + |
| Pruritus | + | + | − | + | − | − | − | − | − | − | − | − |
| Pain or burning | + | − | − | − | − | − | − | − | + | − | − | − |
| Ulceration | + | − | − | − | − | − | − | − | + | − | − | − |
| Laboratory finding | ||||||||||||
| Leucocyte count- × 10−9/l | 4·8 | NA | 4·5 | NA | 5·6 | 6·6 | 5·2 | 4·8 | 5·4 | 5·5 | 5·8 | 6·7 |
| Lymphocyte count- × 10−9/l | 2·0 | NA | 2·7 | NA | 2·0 | 1·3 | 0·75 | 2·4 | 1·2 | 1·7 | 2·9 | 3·2 |
| Neutrophil count- × 10−9/l | 2·6 | NA | 1·6 | NA | 3·0 | 5·1 | 4·3 | 2·2 | 4·0 | 3·7 | 2·7 | 2·8 |
| Platelet count- × 10−9/l | 180 | NA | 230 | NA | 197 | 198 | 378 | 234 | 143 | 231 | 258 | 367 |
| AST-U/l | 59 | NA | 10 | NA | 18 | NA | NA | 28 | NA | NA | NA | 26 |
| ALT-U/l | 71 | NA | 19 | NA | 36 | NA | NA | 45 | NA | NA | NA | 78 |
| Hospitalization-days | 14 | − | − | − | 28 | − | − | 15 | 14 | − | − | 14 |
| Co-infection | − | − | − | − | − | − | − | − | − | SFGR | SFGR | SFGR |
aData is the reciprocal of the serum dilution; bNumber of days after the onset of illness for patients in the acute or the convalescent phase of the illness.
RNA-seq, RNA sequencing; RPM, reads per million; NA, not available (no samples were collected or not reported); AST, aspartate aminotransferase, ALT, alanine aminotransferase; SFGR, spotted fever group Rickettsia.